Comparison of study designs used to detect and characterize pharmacogenomic interactions in nonexperimental studies: A simulation study

Pharmacogenetics and Genomics

Volumn 24, Issue 3, 2014, Pages 146-155

  Avery, Christy L ^a   Der, Jane S ^a   Whitsel, Eric A ^a,b   Stürmer, Til ^a  

^a University of North Carolina at Chapel Hill   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Confounding; Genetic epidemiology; QT interval; Study design

Indexed keywords

ADULT; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG GENE INTERACTION; DRUG INTERACTION; DRUG USE; GENE INTERACTION; HUMAN; MALE; MIDDLE AGED; OBSERVATIONAL STUDY; OVERALL POPULATION DESIGN; PHARMACOGENOMICS; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; SIMULATION; SINGLE NUCLEOTIDE POLYMORPHISM; STUDY DESIGN; TREATED ONLY DESIGN;

ALGORITHMS; ATHEROSCLEROSIS; COMPUTER SIMULATION; ELECTROCARDIOGRAPHY; HUMANS; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; RESEARCH DESIGN;

EID: 84894068441     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0000000000000027     Document Type: Article

References (43)

1. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: A meta-Analysis of prospective studies. JAMA 1998; 279:1200-1205
2. Aronson JK, Ferner RE. Joining the DoTS: New approach to classifying adverse drug reactions. BMJ 2003; 327:1222-1225
3. Khoury MJ, Gwinn M, Clyne M, Yu W. Genetic epidemiology with a capital E, ten years after. Genet Epidemiol 2011; 35:845-852
4. Daneshjou R, Tatonetti NP, Karczewski KJ, Sagreiya H, Bourgeois S, Drozda K, et al. Pathway analysis of genome-wide data improves warfarin dose prediction. BMC Genomics 2013; 14 (Suppl 3):S11
5. Niinuma Y, Saito T, Takahashi M, Tsukada C, Ito M, Hirasawa N, Hiratsuka M. Functional characterization of 32 CYP2C9 allelic variants. Pharmacogenomics J 2013 (in press
6. Perera MA, Cavallari LH, Limdi NA, Gamazon ER, Konkashbaev A, Daneshjou R, et al. Genetic variants associated with warfarin dose in African-American individuals: A genome-wide association study. Lancet 2013; 382:790-796
7. Fellay J, Thompson AJ, Ge D, Gumbs CE, Urban TJ, Shianna KV, et al. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature 2010; 464:405-408
8. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-Treated, node-negative breast cancer. N Engl J Med 2004; 351:2817-2826
9. Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, et al. SLCO1B1 variants and statin-induced myopathy-A genomewide study. N Engl J Med 2008; 359:789-799
10. Volpi S, Heaton C, Mack K, Hamilton JB, Lannan R, Wolfgang CD, et al. Whole genome association study identifies polymorphisms associated with QT prolongation during iloperidone treatment of schizophrenia. Mol Psychiatry 2009; 14:1024-1031
11. Aberg K, Adkins DE, Liu Y, McClay JL, Bukszar J, Jia P, et al. Genome-wide association study of antipsychotic-induced QTc interval prolongation. Pharmacogenomics J 2012; 12:165-172
12. Van Winkel R, Moons T, Peerbooms O, Rutten B, Peuskens J, Claes S, et al. MTHFR genotype and differential evolution of metabolic parameters after initiation of a second generation antipsychotic: An observational study. Int Clin Psychopharmacol 2010; 25:270-276
13. Kaab S, Crawford DC, Sinner MF, Behr ER, Kannankeril PJ, Wilde AA, et al. A large candidate gene survey identifies the KCNE1 D85N polymorphism as a possible modulator of drug-induced torsades de pointes. Circ Cardiovasc Genet 2012; 5:91-99
14. De Keyser CE, Eijgelsheim M, Hofman A, Sijbrands EJ, Maitland-van der Zee AH, van Duijn CM, et al. Single nucleotide polymorphisms in genes that are associated with a modified response to statin therapy: The Rotterdam Study. Pharmacogenomics J 2011; 11:72-80
15. Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH. Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus. Pharmacogenomics J 2009; 9:242-247
16. Hajjar I, Kritchevsky S, Newman AB, Li R, Yaffe K, Simonsick EM, Lipsitz LA. Renin angiotensin system gene polymorphisms modify angiotensinconverting enzyme inhibitors' effect on cognitive function: The health, aging and body composition study. J Am Geriatr Soc 2010; 58: 1035-1042
17. Lee CR, North KE, Bray MS, Couper DJ, Heiss G, Zeldin DC. Cyclooxygenase polymorphisms and risk of cardiovascular events: The Atherosclerosis Risk in Communities (ARIC) study. Clin Pharmacol Ther 2008; 83:52-60
18. ARIC Investigators. The Atherosclerosis Risk in Communities (ARIC) Study: Design and objectives. The ARIC investigators. Am J Epidemiol 1989; 129:687-702
19. Havlik RJ, Garrison RJ, Fabsitz R, Feinleib M. Variability of heart rate, P-R, QRS and Q-T durations in twins. J Electrocardiol 1980; 13:45-48
20. Newton-Cheh C, Larson MG, Corey DC, Benjamin EJ, Herbert AG, Levy D, et al. QT interval is a heritable quantitative trait with evidence of linkage to chromosome 3 in a genome-wide linkage analysis: The Framingham Heart Study. Heart Rhythm 2005; 2:277-284
21. Vaidean GD, Schroeder EB, Whitsel EA, Prineas RJ, Chambless LE, Perhac JS, et al. Short-Term repeatability of electrocardiographic spatial T-wave axis and QT interval. J Electrocardiol 2005; 38:139-147
22. Pratt CM, Ruberg S, Morganroth J, McNutt B, Woodward J, Harris S, et al. Dose-response relation between terfenadine (Seldane) and the QTc interval on the scalar electrocardiogram: Distinguishing a drug effect from spontaneous variability. Am Heart J 1996; 131:472-480
23. McAllister RG Jr, Kirsten EB. The pharmacology of verapamil. IV. Kinetic and dynamic effects after single intravenous and oral doses. Clin Pharmacol Ther 1982; 31:418-426
24. Yap YG, Camm AJ. Drug induced QT prolongation and torsades de pointes. Heart 2003; 89:1363-1372
25. Zhang Y, Post WS, Blasco-Colmenares E, Dalal D, Tomaselli GF, Guallar E. Electrocardiographic QT interval and mortality: A meta-Analysis. Epidemiology 2011; 22:660-670
26. Newton-Cheh C, Eijgelsheim M, Rice KM, de Bakker PI, Yin X, Estrada K, et al. Common variants at ten loci influence QT interval duration in the QTGEN Study. Nat Genet 2009; 41:399-406
27. Pfeufer A, Sanna S, Arking DE, Muller M, Gateva V, Fuchsberger C, et al. Common variants at ten loci modulate the QT interval duration in the QTSCD Study. Nat Genet 2009; 41:407-414
28. Avery CL, Sitlani CM, Arking DE, Arnett DK, Bis JC, Boerwinkle E, et al. Drug-gene interactions and the search for missing heritability: A crosssectional pharmacogenomics study of the QT interval. Pharmacogenomics J 2013; (in press
29. Benoit SR, Mendelsohn AB, Nourjah P, Staffa JA, Graham DJ. Risk factors for prolonged QTc among US adults: Third National Health and Nutrition Examination Survey. Eur J Cardiovasc Prev Rehabil 2005; 12:363-368
30. Geneletti S, Gallo V, Porta M, Khoury MJ, Vineis P. Assessing causal relationships in genomics: From Bradford-Hill criteria to complex geneenvironment interactions and directed acyclic graphs. Emerg Themes Epidemiol 2011; 8:1-18
31. Greenland S, Pearl J, Robins JM. Causal diagrams for epidemiologic research. Epidemiology 1999; 10:37-48
32. Robbins J, Nelson JC, Rautaharju PM, Gottdiener JS. The association between the length of the QT interval and mortality in the Cardiovascular Health Study. Am J Med 2003; 115:689-694
33. Merri M, Benhorin J, Alberti M, Locati E, Moss AJ. Electrocardiographic quantitation of ventricular repolarization. Circulation 1989; 80:1301-1308
34. Lepeschkin E, Surawicz B. The duration of the Q-U interval and its components in electrocardiograms of normal persons. Am Heart J 1953; 46:9-20
35. Albert PS, Ratnasinghe D, Tangrea J, Wacholder S. Limitations of the caseonly design for identifying gene-environment interactions. Am J Epidemiol 2001; 154:687-693
36. Bross ID. Spurious effects from an extraneous variable. J Chronic Dis 1966; 19:637-647
37. Manning AK, LaValley M, Liu CT, Rice K, An P, Liu Y, et al. Meta-Analysis of gene-environment interaction: Joint estimation of SNP and SNP-environment regression coefficients. Genet Epidemiol 2011; 35: 11-18
38. Ottman R. Gene-environment interaction: Definitions and study designs. Prev Med 1996; 25:764-770
39. Brennan P. Gene-environment interaction and aetiology of cancer: What does it mean and how can we measure it? Carcinogenesis 2002; 23: 381-387
40. Rothman KJ. Epidemiology: An introduction. Measuring interactions. 2nd ed. Oxford: University Press; 2012. pp. 198-210
41. Andersson T, Alfredsson L, Kallberg H, Zdravkovic S, Ahlbom A. Calculating measures of biological interaction. Eur J Epidemiol 2005; 20:575-579
42. Rothman KJ. The estimation of synergy or antagonism. Am J Epidemiol 1976; 103:506-511
43. Wilke RA, Xu H, Denny JC, Roden DM, Krauss RM, McCarty CA, et al. The emerging role of electronic medical records in pharmacogenomics. Clin Pharmacol Ther 2011; 89:379-386